Biogen advances Alzheimer’s tau program despite midphase miss
A phase 2 trial of Biogen and Ionis Pharmaceuticals’ tau-targeting candidate missed its primary endpoint. But while the Alzheimer’s disease trial failed to yiel...
A phase 2 trial of Biogen and Ionis Pharmaceuticals’ tau-targeting candidate missed its primary endpoint. But while the Alzheimer’s disease trial failed to yield the hoped-for dose-response data, reductions in tau pathology and cognitive benefits persuaded Biogen to commit to registrational development.